Background & Aims Fecal microbiota–based therapies include conventional fecal microbiota
transplant and US Food and Drug Administration–approved therapies, fecal microbiota live …

Background Irritable bowel syndrome (IBS) is a common gastrointestinal functional disorder.
Although IBS is a benign condition, it reduces the quality of life considerably. While there is …

The intestinal microbiota plays an important role in maintaining human health, and its
alteration is now associated with the development of various gastrointestinal (ulcerative …

Objective Whether fecal microbiota transplantation (FMT) in patients with irritable bowel
syndrome (IBS) is effective in improving outcomes remains controversial. We assessed the …

We are in the midst of “the microbiome revolution”—not a day goes by without some new
revelation on the potential role of the gut microbiome in some disease or disorder. From an …

Background Severity in irritable bowel syndrome (IBS) is associated to impaired quality of
life and fatigue. Fecal microbiota transplantation (FMT) induces significant relief in gastro …

The intestinal microbiome has been identified as a key modifier for a variety of health
conditions. Fecal Microbiota Transplantation (FMT) has emerged as a fast, safe, and …

Fecal microbiome transplant (FMT) has gained popularity over the past few years, given its
success in treating several gastrointestinal diseases. At the same time, microbial …

Fecal microbiota transplantation (FMT) has demonstrated efficacy in treating inflammatory
bowel diseases and irritable bowel syndrome in an increasing number of randomized …

Irritable bowel syndrome (IBS) poses a significant challenge due to its poorly understood
pathogenesis, substantial morbidity, and often inadequate treatment outcomes. The role of …